Annovis Bio, Inc.
ANVS
$1.25
-$0.05-3.85%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.37M | 1.19M | 955.20K | 1.14M | 1.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.38M | 17.91M | 9.71M | 7.44M | 6.27M |
| Operating Income | -14.38M | -17.91M | -9.71M | -7.44M | -6.27M |
| Income Before Tax | -14.82M | -17.61M | -9.83M | -7.26M | -6.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.82M | -17.61M | -9.83M | -7.26M | -6.22M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.82M | -17.61M | -9.83M | -7.26M | -6.22M |
| EBIT | -14.38M | -17.91M | -9.71M | -7.44M | -6.27M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.40 | -0.63 | -0.38 | -0.37 | -0.32 |
| Normalized Basic EPS | -0.25 | -0.39 | -0.24 | -0.23 | -0.20 |
| EPS Diluted | -0.40 | -0.63 | -0.38 | -0.37 | -0.32 |
| Normalized Diluted EPS | -0.25 | -0.39 | -0.24 | -0.23 | -0.20 |
| Average Basic Shares Outstanding | 37.52M | 27.85M | 25.58M | 19.69M | 19.49M |
| Average Diluted Shares Outstanding | 37.52M | 27.85M | 25.58M | 19.69M | 19.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |